Vasa

Vasa Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing transformative therapies for cardiovascular, neuromuscular, and metabolic aging. The company's lead clinical candidate, VS-041, is an oral small molecule inhibitor of MMP-2 and MMP-9 currently in a Phase 1c proof-of-mechanism trial for heart failure with preserved ejection fraction (HFpEF). Vasa is also developing a library of long-acting apelin receptor agonists, including VS-214 and VS-241, to treat peripheral artery disease, sarcopenia, and rare neuromuscular diseases. Additionally, the company is advancing a CaMKII delta inhibitor program for heart failure and life-threatening arrhythmias, utilizing Eli Lilly's TuneLab AI-enabled drug discovery platform to accelerate candidate selection.